GelfandJMGladmanDDMeasePJ. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol2005;53:573.
2.
TaylorWGladmanDHelliwellP; CASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum2006;54:2665–73.
3.
ChandranVSchentagCTGladmanDD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum2007;57:1560–3.
4.
WrightVMollJMH. Psoriatic arthritis. In: WrightVMollJMH, editors. Seronegative polyarthritis. Amsterdam: North Holland Publishing Co; 1976. p. 169–223.
5.
GladmanDD. Psoriatic arthritis. In: GordonKRudermanE, editors. Psoriasis and psoriatic arthritis. Berlin: Springer-Verlag; 2005. p. 57–65.
6.
KhanMSchentagCGladmanD. Clinical and radiological changes during psoriatic arthritis disease progression: Working toward classification criteria. J Rheumatol2003;30:1022–6.
7.
MeasePJOryPSharpJT. Adalimumab sustains inhibition of joint damage for more than 2 years in patients with PsA [abstract]. Ann Rheum Dis2008;67Suppl II:99.
8.
ZachariaeH. Prevalence of joint disease in patients with psoriasis: Implications for therapy. Am J Clin Dermatol2003;4:441–7.
9.
BrockbankJESchentagCRosenCGladmanDD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees [abstract]. Arthritis Rheum2001;44Suppl 9:S94.
10.
GladmanDDAntoniCMeaseP. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis2005;64Suppl 2:ii14-–7.
11.
CohenMRRedaDJCleggDO. Baseline relationships between psoriasis and psoriatic arthritis: Analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol1999;26:1752–6.
12.
ChandranVCookRHelliwellP. International Multi-centre Psoriasis and Psoriatic Arthritis Reliability Trial (GRAPPA-IMPART): Assessment of skin, joints, nails and dactylitis. Arthritis Rheum2007;56Suppl 9:S798.
13.
GladmanDDSchentagCTTomBD. Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis2009;68:497–501.
14.
RitchlinCTKavanaughAGladmanDD. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis.2009;68;1387–94
15.
SaadAASymmonsDPNoycePRAshcroftDM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials. J Rheumatol2008;35:883–90.
16.
GladmanDD. Adalimumab, etanercept, and infliximab are equally effective treatments for patients with psoriatic arthritis. Nat Clin Pract Rheumatol2008;4:510–1.
